Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial

• Published in: Canadian journal of gastroenterology & hepatology Vol. 2017; no. 2017; pp. 1 - 7
• Main Authors: Matsuda, Yoshiaki, Wada, Shuichi, Horiuchi, Akira, Kiyosawa, Kendo, Fujisawa, Toru, Imai, Ryujiro, Tokutake, Koujiro, Kimura, Takefumi, Miyajima, Masayuki, Kubota, Daisuke, Tanaka, Naoki, Maruyama, Masafumi, Mori, Hiromitsu
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; Hindawi Limited; John Wiley & Sons, Inc; Wiley
• Subjects: Acids; Adult; Aged; Aged, 80 and over; Amoxicillin - therapeutic use; Antacids; Anti-Bacterial Agents - therapeutic use; Antibiotics; Clarithromycin - therapeutic use; Clinical Study; Clinical trials; Comparative analysis; Drug therapy; Drug Therapy, Combination; Female; Gastric cancer; Gastroenterology; Helicobacter infections; Helicobacter Infections - drug therapy; Helicobacter pylori - drug effects; Hospitals; Humans; Japan; Lansoprazole - therapeutic use; Male; Metabolism; Middle Aged; Potassium; Proton pump inhibitors; Proton Pump Inhibitors - therapeutic use; Pyrroles - therapeutic use; Rabeprazole - therapeutic use; Single-Blind Method; Sulfonamides - therapeutic use; Treatment Outcome; Ulcers

Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized...